Accuray (0H8I) Share Price & Analysis
0H8I Stock Chart & Stats
- Day’s Range
- $0.13 - $0.14
- 52-Week Range
- $0.12 - $1.45
- Previous Close
- $0.14
- Volume
- 408
- Average Volume (3M)
- 773.07K
- Market Cap
- $16.74M
- Enterprise Value
- $179.06M
- Total Cash (Recent Filing)
- $40.62M
- Total Debt (Recent Filing)
- $183.87M
- Price to Earnings (P/E)
- ―
- Beta
- 0.46
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Service Strength
Service revenue growth and a contract capture rate near 90% support recurring, relatively predictable business activity. Pricing actions, an expanding installed base, and out-of-contract billing opportunities can sustain service economics and provide a steadier foundation while equipment demand remains uneven.
Transformation Savings
Exceeding the cost and margin improvement target demonstrates measurable progress in operational restructuring. The expected approximately $15M of incremental annualized benefit in FY27 could improve profitability and cash conversion, provided demand conditions allow the savings to flow through results.
Financing And Liquidity Support
Approved financing measures are designed to reduce leverage, add liquidity, and extend the company’s operating runway. Converting $40M of term debt and securing covenant relief through late 2027 should provide more time to execute transformation initiatives and stabilize the business.
Bears Say
Product Revenue Contraction
The sharp decline in product revenue indicates substantial weakness in demand for Accuray’s equipment business, which remains important to overall growth. Prolonged shipment pressure can reduce scale, weaken the product mix, and limit the company’s ability to offset fixed operating costs.
High Leverage And Cash Burn
Very high leverage combined with negative recent cash generation leaves Accuray with less financial flexibility. A thinner equity cushion increases the consequences of continued operating weakness, while cash burn can constrain investment, debt management, and the ability to absorb further setbacks.
Weak Orders And Limited Visibility
Book-to-bill below management’s healthy target suggests that incoming equipment orders are not yet strong enough to support dependable near-term growth. Withholding FY27 guidance because of demand and macro uncertainty further indicates limited visibility into revenue recovery and earnings progression.
Accuray News
0H8I FAQ
What was Accuray’s price range in the past 12 months?
What is Accuray’s market cap?
When is Accuray’s upcoming earnings report date?
How were Accuray’s earnings last quarter?
Is Accuray overvalued?
Does Accuray pay dividends?
What is Accuray’s EPS estimate?
How many shares outstanding does Accuray have?
What happened to Accuray’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Accuray?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Accuray
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Stephen R. LaNeve
- Employees
- 809
- Website
- www.accuray.com
- Address
- 1240 Deming Way, Madison, WI, 53717-1954, US
Accuray (0H8I) Earnings & Revenues
0H8I Company Deck
0H8I Earnings Call
Earnings Call SentimentNeutral
The call presented a balanced mix of encouraging operational progress and continued material challenges. Positive developments include service revenue growth, improved service margins, realization of more than $20M in transformation savings (with an expected ~$15M annualized benefit), improved Q4 adjusted EBITDA and operating income, reduced inventory and an announced financing transaction with TCW that should materially strengthen liquidity and capital structure if completed. On the negative side, the company reported significant declines in product revenue (Q4 -42% YoY; FY -27% YoY), weaker product margins when excluding tariff favorability, a FY operating loss of $26.4M, a fall in trailing book-to-bill below the company target, and ongoing geopolitical/tariff uncertainty (notably China) that materially curtailed sales visibility and led management to withhold formal FY27 revenue/EBITDA guidance. Overall, the call signals that the company has made important progress on cost, service and financing initiatives, but persistent product demand and regional/tariff headwinds remain significant near-term risks.
View all GB:0H8I earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 13 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 1 | 0 | 11 |









